bluebird bio Announces Pricing of Public Offering of Common Stock
December 06 2016 - 9:49PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage
biotechnology company committed to developing potentially
transformative gene therapies for severe genetic diseases and
cancer, today announced the pricing of an underwritten public
offering of 3,289,473 shares of its common stock at a public
offering price of $76.00 per share, before underwriting discounts.
In addition, bluebird bio has granted the underwriters a 30-day
option to purchase up to an additional 493,420 shares of common
stock. All of the shares in the offering are to be sold by bluebird
bio.
Goldman, Sachs & Co., BofA Merrill Lynch and Cowen and
Company are acting as joint book-running managers of the offering.
Wells Fargo Securities and Wedbush PacGrow are acting as
co-managers. The offering is expected to close on or about
December 12, 2016, subject to customary closing
conditions.
bluebird bio anticipates the total gross proceeds from the
offering (before deducting underwriters’ discounts and commissions
and estimated offering expenses) will be approximately $250
million, excluding any exercise of the underwriters’ option to
purchase additional shares.
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was
previously filed with the Securities and Exchange Commission (SEC).
A preliminary prospectus supplement relating to and describing the
terms of the offering was filed with the SEC on December 6, 2016.
The final prospectus supplement relating to the offering will be
filed with the SEC and will be available on the SEC’s website at
www.sec.gov. When available, copies of the final prospectus
supplement and the accompanying prospectus relating to these
securities may also be obtained by contacting one of the following:
Goldman, Sachs & Co., Attn: Prospectus Department, 200 West
Street, New York, NY 10282, telephone: (212) 902-1171, facsimile:
(212) 902-9316, email: prospectus-ny@ny.email.gs.com; BofA Merrill
Lynch, NC1-004-03-43, 200 North College Street, 3rd floor,
Charlotte, NC 28255-0001, Attn: Prospectus Department, email:
dg.prospectus_requests@baml.com; or Cowen and Company, LLC, c/o
Broadridge Financial Services, 1155 Long Island Avenue, Edgewood,
NY, 11717, Attn: Prospectus Department, by telephone at (631)
274-2806 or by fax at (631) 254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing
capabilities, bluebird bio has built an integrated product platform
with broad potential application to severe genetic diseases and
cancer. bluebird bio’s gene therapy clinical programs include its
Lenti-D™ product candidate, currently in a Phase 2/3 study, called
the Starbeam Study, for the treatment of cerebral
adrenoleukodystrophy, and its LentiGlobin® BB305 product candidate,
currently in four clinical studies for the treatment of
transfusion-dependent beta-thalassemia and severe sickle cell
disease. bluebird bio’s oncology pipeline is built upon the
company’s leadership in lentiviral gene delivery and T cell
engineering, with a focus on developing novel T cell-based
immunotherapies, including chimeric antigen receptor (CAR T) and T
cell receptor (TCR) therapies. bluebird bio’s lead oncology
program, bb2121, is an anti-BCMA CAR T program partnered with
Celgene. bb2121 is currently being studied in a Phase 1 trial for
the treatment of relapsed/refractory multiple myeloma. bluebird bio
also has discovery research programs utilizing megaTALs/homing
endonuclease gene editing technologies with the potential for use
across the company’s pipeline.
bluebird bio has operations in Cambridge, Massachusetts,
Seattle, Washington, and Paris, France.
Forward-Looking Statements
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding the anticipated final terms, timing
and completion of the offering, and bluebird bio’s existing product
candidates and research programs. Any forward-looking statements
are based on management’s current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to, risks and
uncertainties related to market conditions and satisfaction of
customary closing conditions related to the public offering, that
the preliminary positive results from our prior and ongoing
clinical trials will not continue or be repeated in our ongoing,
planned or expanded clinical trials, the risk that the changes we
have made in the LentiGlobin manufacturing process or the HGB-206
clinical trial protocol will not result in improved patient
outcomes, the risk that the current or planned clinical trials of
LentiGlobin and Lenti-D will be insufficient to support regulatory
submissions or marketing approval in the United States and European
Union, the risk of cessation or delay of any of the ongoing or
planned clinical studies and/or our development of our product
candidates, the risk of a delay in the enrollment of patients in
our clinical studies, and the risk that any one or more of our
product candidates will not be successfully developed and
commercialized. There can be no assurance that bluebird bio will be
able to complete the public offering on the anticipated terms, or
at all. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in our most
recent quarterly report on Form 10-Q, as well as discussions of
potential risks, uncertainties, and other important factors in our
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and bluebird bio undertakes no duty to update this information
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161206006547/en/
Investor Relationsbluebird bio, Inc.Manisha Pai,
617-245-2107mpai@bluebirdbio.comorMedia Contactbluebird bio,
Inc.Elizabeth Pingpank, 617-914-8736epingpank@bluebirdbio.comorPure
Communications, Inc.Dan Budwick, 973-271-6085
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024